Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AstraZeneca Japan Set to Buttress Respiratory Business with Tezspire Debut
December 2, 2022
-
BUSINESS Ultragenyx to Ramp Up Ultra-Orphan Drug Development, Bolster Hiring in Japan
December 1, 2022
-
BUSINESS Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan
December 1, 2022
-
REGULATORY MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
November 30, 2022
-
BUSINESS No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
November 30, 2022
-
REGULATORY Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
November 29, 2022
-
COMMENTARY Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
-
BUSINESS Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
November 25, 2022
-
REGULATORY Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
November 24, 2022
-
COMMENTARY Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
November 22, 2022
-
ACADEMIA Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
November 21, 2022
-
BUSINESS Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
November 18, 2022
-
BUSINESS Merck R&D Chief Confident on Expanding Pipeline towards Keytruda Patent Cliff and Beyond
November 17, 2022
-
BUSINESS Top 4 Wholesalers on Recovery Trend, Operating Profit Up 69.1% in April-September
November 16, 2022
-
BUSINESS Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
November 15, 2022
-
REGULATORY Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
November 15, 2022
-
BUSINESS Asian Regulatory Harmonization Underutilized by Japan Drug Makers, Priorities on Western Markets
November 14, 2022
-
REGULATORY Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
-
REGULATORY Zero Coefficient Rule Hits All 10 Premium-Granted Drugs Priced by Cost Formula in FY2022
November 11, 2022
-
REGULATORY Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
November 10, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…